We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-10.8%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$912M
AUM Growth
-$128M
Cap. Flow
+$54.4M
Cap. Flow %
5.96%
Top 10 Hldgs %
97.27%
Holding
17
New
3
Increased
3
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
CRVS icon
Corvus Pharmaceuticals
CRVS
+$45.3M
2
XLRN
Acceleron Pharma
XLRN
+$19.6M
3
SPNC
Spectranetics Corp
SPNC
+$3.28M
4
PEN icon
Penumbra
PEN
+$1.26M
5
GKOS icon
Glaukos
GKOS
+$453K

Top Sells

Rank Stock Value
1
VTI icon
Vanguard Total Stock Market ETF
VTI
+$14.1M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$1.43M

Sector Composition

Rank Sector Weight
1 Healthcare 55.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$653B
$297M 32.59%
2,837,100
-142,000
-5% -$14.1M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$208M 22.75%
4,910,487
– –
INGN icon
3
Inogen
INGN
$172M
$160M 17.5%
3,549,320
– –
VGK icon
4
Vanguard FTSE Europe ETF
VGK
$30.1B
$102M 11.17%
2,101,000
– –
CRVS icon
5
Corvus Pharmaceuticals
CRVS
$1.1B
$45.7M 5.01%
+3,154,046
New +$45.3M
CLCD
6
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$19M 2.08%
3,056,563
– –
TBRA
7
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$18.7M 2.05%
2,281,405
-190,000
-8% -$1.43M
XLRN
8
DELISTED
Acceleron Pharma
XLRN
$17.8M 1.95%
+673,063
New +$19.6M
PEN icon
9
Penumbra
PEN
$12.6B
$12.1M 1.33%
263,191
+27,047
+11% +$1.26M
NBRV
10
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$7.84M 0.86%
3,500
– –
IVTY
11
DELISTED
Invuity, Inc
IVTY
$6.76M 0.74%
936,193
+11,193
+1% +$86.2K
WMGIZ
12
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
0
– –
HTGM
13
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$3.67M 0.4%
7,112
– –
SPNC
14
DELISTED
Spectranetics Corp
SPNC
$3.44M 0.38%
+236,826
New +$3.28M
ELDN icon
15
Eledon Pharmaceuticals
ELDN
$278M
$2.64M 0.29%
2,907
– –
GKOS icon
16
Glaukos
GKOS
$8.72B
$1.71M 0.19%
101,106
+26,106
+35% +$453K
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.32B
$892K 0.1%
127,563
– –

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q1 2016 Portfolio in Review

As of Q1 2016, Novo Holdings A/S held 17 positions worth $912M, down 12% from $1.04B the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Novo Holdings A/S deployed $54.4M of net new capital in Q1 2016, opening 3 new positions and adding to 3 existing holdings. Its largest new stake was Corvus Pharmaceuticals: 3,154,046 shares worth $45.7M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 60% a quarter earlier.

On the sell side, the largest reduction was Vanguard Total Stock Market ETF, an estimated $14.1M trimmed.

  • Novo Holdings A/S's largest Q1 2016 buy was Corvus Pharmaceuticals: 3,154,046 shares worth $45.7M.
  • Novo Holdings A/S added most to Penumbra in Q1 2016, an estimated $1.26M increase.
  • Novo Holdings A/S's biggest Q1 2016 reduction was Vanguard Total Stock Market ETF, cutting an estimated $14.1M.
  • Novo Holdings A/S's ten largest holdings make up 97% of its $912M portfolio in Q1 2016.
  • Novo Holdings A/S opened 3 new positions and closed 0 in Q1 2016.
  • Novo Holdings A/S's portfolio value fell 12% quarter-over-quarter to $912M.

Based on Novo Holdings A/S's 13F filing for Q1 2016, filed 16 May 2016.